Maxillary sinus augmentation encompasses surgical methods designed to increase bone volume in the posterior maxilla to support dental implants. Two principal approaches are employed: the lateral ...

Lower health care utilization was shown in patients with chronic rhinosinusitis, with and without nasal polyps, who had steroid-eluting implants vs those who did not in the 18 months following ...

MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced the results of a ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced publication of a ...

MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that ...

Intersect ENT showed it has another device to add to its line of sinus implants, touting positive data from a pilot study of its new steroid delivery implant to treat chronic sinusitis. The ...

Placed during a routine physician office visit, SINUVA expands in the sinus cavity and delivers an anti-inflammatory steroid directly to the site of polyp disease for up to 90 days. SINUVA was ...

DrBicuspid.com is pleased to present the next column from two lawyers who spend every day defending dentists in litigation and before the licensing board. The purpose of this column is to offer our ...

Intersect ENT received CMS approval of a revised coding application for its Propel sinus implant, according to a Jan. 19 news release. Propel previously shared a billing code with Intersect ENT’s ...